Company Analysis
Sign in

Lyell Immunopharma, Inc. (LYEL)

Nasdaq: LYEL · Pharmaceutical Preparations · South San Francisco, CA · filing with the SEC since 2020
Full chart Alerts Compare
Grade3.5
◀ Past 3.8● Present 3.4▶ Future 3.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

5 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Lyell Immunopharma, Inc.’s names, not what it holds today.

Patents granted
5
5 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 3 in 2024 and none in 2023
Applications published
19
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology3
Medical technology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
LYELL IMMUNOPHARMA, INC. its own name
US, as the owner printed on each patent
5 granted
17 published
Lyell Immunopharma, Inc. its own name
named as the applicant on its applications, in US
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Jul 22, 202512,365,871Methods for culturing cellsMedical technologyLYELL IMMUNOPHARMA, INC.
Apr 8, 202512,270,032Codon-optimized nucleotide sequences encoding an AP-1 transcription factorBiotechnologyLYELL IMMUNOPHARMA, INC.
Nov 19, 202412,144,827ROR1 targeting chimeric antigen receptorBiotechnologyLYELL IMMUNOPHARMA, INC.
Sep 17, 202412,091,682Methods for making, compositions comprising, and methods of using rejuvenated T cellsMedical technologyLYELL IMMUNOPHARMA, INC.
Aug 6, 202412,054,531Recombinant cell surface markersBiotechnologyLYELL IMMUNOPHARMA, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Sep 25, 20252025/0297268CODON-OPTIMIZED NUCLEOTIDE SEQUENCES ENCODING AN AP-1 TRANSCRIPTION FACTORBiotechnologyLYELL IMMUNOPHARMA, INC.
Jul 17, 20252025/0228939ENHANCED IMMUNE CELL THERAPYBiotechnologyLyell Immunopharma, Inc.
May 15, 20252025/0154458Methods for Making, Compositions Comprising, and Methods of Using Rejuvenated T CellsMedical technologyLYELL IMMUNOPHARMA, INC.
Dec 12, 20242024/0409610Novel Recombinant Cell Surface MarkersBiotechnologyLYELL IMMUNOPHARMA, INC.
Nov 14, 20242024/0374725NR4A3-DEFICIENT IMMUNE CELLS AND USES THEREOFBiotechnologyLYELL IMMUNOPHARMA, INC.
Jul 11, 20242024/0228957METHODS FOR CULTURING CELLSMedical technologyLYELL IMMUNOPHARMA, INC.
Apr 25, 20242024/0132840METHODS FOR CULTURING CELLSMedical technologyLYELL IMMUNOPHARMA, INC.
Dec 14, 20232023/0398216CHIMERIC ACTIVATION RECEPTORSBiotechnologyLYELL IMMUNOPHARMA, INC.
Oct 5, 20232023/0313138METHODS FOR CULTURING CELLS EXPRESSING C-JUNBiotechnologyLYELL IMMUNOPHARMA, INC.
Oct 5, 20232023/0310605METHODS FOR CULTURING CELLS EXPRESSING ROR1-BINDING PROTEINBiotechnologyLYELL IMMUNOPHARMA, INC.
What it applied for, 2024 to 2025: Biotechnology 4 · Medical technology 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton LYEL · research, not advice